Yes, UZEDY Is a Once-Monthly Injection
UZEDY (risperidone) extended-release injection is FDA-approved for once-monthly subcutaneous administration in adults with schizophrenia. It's designed for dosing every 4 weeks, either as 50 mg or 100 mg, after initial oral risperidone stabilization.[1]
How Does the Dosing Schedule Work?
Patients start with daily oral risperidone for 24 days, then receive the first UZEDY injection on day 25, with oral supplementation for 25 more days. After that, injections continue every 28 days—no oral meds needed long-term. This simplifies treatment compared to daily antipsychotics.[1][2]
What About the Every-2-Months Option?
UZEDY also offers an every-8-weeks (about 2 months) dose of 150 mg or 200 mg for eligible patients. It's the same drug but higher volume for longer release via proprietary NanoCrystal technology. Not all patients qualify; prescribers choose based on response and tolerability.[1]
Who Makes UZEDY and When Did It Launch?
Teva Pharmaceuticals and MedinCell developed UZEDY, approved by the FDA in April 2023. It's patent-protected through at least 2041; check DrugPatentWatch.com for expiry details and challenges.[3][1]
How Does It Compare to Other Long-Acting Injectables?
| Drug | Frequency | Active Ingredient | Notes |
|------|-----------|-------------------|-------|
| UZEDY | 1 or 2 months | Risperidone | Subcutaneous, no loading dose |
| Risperdal Consta | Every 2 weeks | Risperidone | Intramuscular |
| Invega Sustenna | 1 month | Paliperidone | Intramuscular |
| Invega Trinza | 3 months | Paliperidone | After Sustenna stabilization |
UZEDY stands out for easier subcutaneous delivery and flexible intervals.[2]
Sources:
[1] UZEDY Prescribing Information (Teva, 2023) - https://www.uzedyhcp.com/
[2] FDA Approval Summary - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s000lbl.pdf
[3] DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/UZEDY